1. 36 DRUGS
10 COMPANIESDRUGS
2014 YEAR IN REVIEW
FDA
DRUG APPROVALS
Novel Drugs Approved in 2014
APPROVED

2. Type 2 Diabetes
Source: FDA.GOV
FARXIGA
1

3. Non­24­Hour Sleep­Wake Disorder
Source: FDA.GOV
HETLIOZ
2

4. Morquio A Syndrome
Source: FDA.GOV
VIMIZIM
3

5. Neurogenic Orthostatic Hypotension
(NOH)
Source: FDA.GOV
NORTHERA
4

6. Complications of Leptin Deficiency
Source: FDA.GOV
MYALEPT
5

7. Positron Emission Tomography (PET)
Imaging of the Brain
Source: FDA.GOV
NEURACEQ
6

8. Leishmaniasis
Source: FDA.GOV
IMPAVIDO
7

9. Moderate to Severe Plaque Psoriasis
Source: FDA.GOV
OTEZLA
8

10. Type 2 Diabetes
Source: FDA.GOV
TANZEUM
9

11. Advanced Stomach Cancer or
Gastroesophageal Junction
Adenocarcinoma
Source: FDA.GOV
CYRAMZA 10

12. Multicentric Castleman’s Disease (MCD)
Source: FDA.GOV
SYLVANT 11

13. Anaplastic Lymphoma Kinase­Positive
(ALK+) Metastatic Non­Small Cell Lung
Cancer (NSCLC)
Source: FDA.GOV
ZYKADIA 12

14. Reduce Risk of Heart Attacks and Stroke in
High­Risk Patients
Source: FDA.GOV
ZONTIVITY 13

15. Severe Ulcerative Colitis and Adult
Patients with Moderate to Severe Crohn‘s
Disease
Source: FDA.GOV
ENTYVIO 14

16. Acute Bacterial Skin and Skin Structure
Infections
Source: FDA.GOV
DALVANCE 15

17. Toenail Fungus
Source: FDA.GOV
JUBLIA 16

18. Acute Bacterial Skin and Skin Structure
Infections
Source: FDA.GOV
SIVEXTRO 17

19. Peripheral T­Cell Lymphoma (PTCL)
Source: FDA.GOV
BELEODAQ 18

20. Toenail Fungus
Source: FDA.GOV
KERYDIN 19

21. Chronic Lymphocytic Leukemia (CLL)
Follicular B­cell non­Hodgkin Lymphoma
(FL)
Small Lymphocytic Lymphoma (SLL)
Source: FDA.GOV
ZYDELIG 20

22. Chronic Obstructive Pulmonary Disease
(COPD)
Source: FDA.GOV
STRIVERDI
RESPIMAT
21

23. Type 2 Diabetes
Source: FDA.GOV
JARDIANCE 22

24. Type 2 Diabetes
Source: FDA.GOV
ORBACTIV 23

25. Insomnia
Source: FDA.GOV
BELSOMRA 24

26. Relapsing Forms of Multiple Sclerosis (MS)
Source: FDA.GOV
PLEGRIDY 25

27. Gaucher Disease Type 1
Source: FDA.GOV
CERDELGA 26

28. Melanoma
Source: FDA.GOV
KEYTRUDA 27

29. Opioid­Induced Constipation (OIC) in Adult
Patients with Chronic Non‑Cancer Pain
Source: FDA.GOV
MOVANTIK 28

30. Type 2 Diabetes
Source: FDA.GOV
TRULICITY 29

31. Type 2 Diabetes
Source: FDA.GOV
LUMASON 30

32. Nausea and Vomiting in Patients
Undergoing Cancer Chemotherapy
Source: FDA.GOV
AKYNZEO 31

33. Chronic Hepatitis C
Source: FDA.GOV
HARVONI 32

34. Idiopathic Pulmonary Fibrosis (IPF)
Source: FDA.GOV
ESBRIET 33

35. Idiopathic Pulmonary Fibrosis (IPF)
Source: FDA.GOV
OFEV 34

36. Acute Lymphoblastic Leukemia
Source: FDA.GOV
BLINCYTO 35

37. Otitis Externa (Swimmer's Ear)
Source: FDA.GOV
XTORO 36

38. Advanced Ovarian Cancer
Source: FDA.GOV
LYNPARZA 37

39. Chronic Genotype 1 Hepatitis C
Source: FDA.GOV
VIEKIRA PAK 38

40. COMPLICATED URINARY TRACT AND
COMPLICATED INTRA­ABDOMINAL
INFECTIONS
Source: FDA.GOV
ZERBAXA 39

41. Acute Uncomplicated Influenza
Source: FDA.GOV
RAPIVAB 40

42. Advanced Melanoma
Source: FDA.GOV
OPDIVO 41

43. Chronic Weight Management
Source: FDA.GOV
SAXENDA 42

44. Chronic Lymphocytic Leukemia
Source: FDA.GOV
IMBRUVICA 43

45. Type 2 Diabetes
Source: FDA.GOV
INVOKAMET 44

46. Inflammatory Lesions, Bumps and
Pimples, of Rosacea
Source: FDA.GOV
SOOLANTRA 45

47. 36 DRUGS
10
COMPANIES
DRUGS
CREATED BY: